Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy

Abstract

IntroductionApplication of therapeutic folate radioconjugates is a promising option for the treatment of folate receptor (FR)-positive tumors, although high uptake of radiofolates in the kidneys remains a critical issue. Recently, it was shown that enhancing the blood circulation of radiofolates results in increased tumor uptake and reduced retention of radioactivity in the kidneys. In this study, we investigated and compared the anti-tumor effects and potential long-term damage to the kidneys after application of an albumin-binding (177Lu-cm09), and a conventional (177Lu-EC0800) folate radioconjugate. MethodsIn vivo studies were performed with KB tumor-bearing nude mice. 177Lu-EC0800 and 177Lu-cm09 were applied at variable quantities (10–30MBq/mouse), and the tumor growth was monitored over time. Mice without tumors were injected with the same radiofolates and investigated over eight months by determination of creatinine and blood urea nitrogen plasma levels and by measuring renal uptake of 99mTc-DMSA using SPECT. At the study end, the morphological changes were examined on renal tissue sections using variable staining methods. ResultsCompared to untreated controls, dose-dependent tumor growth inhibition and prolonged survival was observed in all treated mice. In line with the resulting absorbed dose, the treatment was more effective with 177Lu-cm09 than with 177Lu-EC0800, enabling complete tumor remission after application of ≥20MBq (≥28Gy). Application of radiofolates with an absorbed renal dose ≥23Gy showed increased levels of renal plasma parameters and reduced renal uptake of 99mTc-DSMA. Morphological changes observed on tissue sections confirmed radionephropathy of variable stages. Conclusions177Lu-cm09 showed more favorable anti-tumor effects and significantly less damage to the kidneys compared to 177Lu-EC0800 as was expected based on improved tumor-to-kidney ratios. It was demonstrated that enhancing the blood circulation time of radiofolates was favorable regarding the risk–benefit profile of a therapeutic application. These results hold promise for future translation of the albumin-binder concept to the clinics, potentially enabling FR-targeted radionuclide therapy in patients.